PLIANT THERAPEUTICS, INC.
PLRX · XNASCIK 1746473fmd_0C4NSZP8YFGRV7K495PWJAWQ3GManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 31 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 57 | 42 | 8 | 10 | 2 | 0 | 0 |
| Research and development | 47 | 66 | 78 | 97 | 128 | 169 | 109 |
| Total operating expenses | 58 | 83 | 105 | 137 | 186 | 228 | 156 |
| Operating income | (1) | (42) | (98) | (127) | (184) | (228) | (156) |
| Interest expense | – | – | 0 | 1 | 1 | 3 | 3 |
| Interest and investment income | 1 | 0 | – | – | – | – | – |
| Other non-operating income (expense) | (0) | (0) | – | – | – | – | – |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (1) | (42) | (97) | (123) | (161) | (210) | (149) |
| Net income to common shareholders | (7) | (42) | (97) | (123) | – | – | – |